Print this page    •   Back to Web version of article

AIDS Treatment News
August 23, 1996

January 1, 1981


  1. Nelfinavir Protease Inhibitor Study Recruiting
  2. Five-Drug or Six-Drug Antiretroviral Therapy - Conversation with Steven Scheibel, M.D.
  3. 1592 -- New Experimental Antiretroviral
  4. Medical Marijuana: California Update
  5. Calendar of AIDS Research and Treatment Meetings, Late 1996 and Beyond

Nelfinavir Protease Inhibitor 
Study Recruiting

A new trial of nelfinavir -- VIRACEPTTM-- the experimental protease inhibitor being developed by Agouron Pharmaceuticals, Inc., is now recruiting 200 volunteers with CD4 count under 100 (measured any time in the last 90 days), who are already taking nucleoside analog drugs (AZT, ddI, ddC, d4T, or 3TC). This trial is being conducted in eight U.S. cities: Berkeley, Chicago, Dallas, Fort Lauderdale, Los Angeles, New York City (2 sites), San Francisco, and St. Paul.

All of the volunteers will receive the same dose of nelfinavir, 750 mg three times a day. Half of them will be randomly assigned to stay on the nucleoside analogs they are currently using; the other half will be assigned to switch to different nucleoside analogs.

For more information, including the specific sites and contact numbers, call 800/501-2474, then dial 1 for a recorded message.

Five-Drug or Six-Drug 
Antiretroviral Therapy -- 
Conversation with Steven Scheibel, M.D.

by John S. James
A small clinical trial and observational study in San Francisco (1) reported very good HIV suppression with regimens of as many as six antiretrovirals. We asked Steven F. Scheibel, M.D., one of the physicians who conducted these studies, for more recent information than is available in the published Vancouver conference abstract.

ATN: We understand that you tried the same five-drug combination in two different groups of patients. First, could you describe the study with patients who were recently infected?

Dr. Scheibel: We treated six patients who were recently HIV-1 infected (within the past 6 months), with a low-dose combination of AZT, ddI, ddC, and interferon-alpha. Most of these patients were also receiving full dose 3TC. For this small group of recent seroconverters, there was a mean 4.5 log decrease in plasma HIV-1 RNA at an average followup of six months. All these patients attained undetectable HIV RNA as measured by the Roche Ultradirect Monitor assay, which has a limit of detection of 10 copies/ml of plasma.

ATN: But wouldn't recently infected patients be expected to have a viral load decline anyway, even without treatment?

Dr. Scheibel: Even though there may be a drop in plasma HIV RNA in untreated recent seroconverters, there is still a measurable HIV RNA level. Overall, in the absence of treatment, one would expect to find a one to two log reduction in viral load [in patients like those who were treated]. Our results suggest that most recent seroconverters can reach undetectable viral load with this treatment -- accompanied by preservation or restoration of CD4 cells. And this was accomplished without using a protease inhibitor, reserving that class of drugs for later use if needed.

ATN: What other results did you find?

Dr. Scheibel: We did a lymph-node biopsy on one patient, at week 78, and found a normal architecture, with no evidence of HIV by in situ hybridization.

ATN: What about persons who have been infected for longer?

Dr. Scheibel: We also conducted extended observation of 15 patients with prolonged HIV infection. They were on the above regimen, and most were also taking one of the approved protease inhibitors. They had a mean drop in HIV RNA of 3.5 log. Many of these patients had undetectable HIV RNA levels when tested with the Roche Ultradirect Monitor assay.

ATN? What research should be done next? What are your future plans?

Dr. Scheibel: Once the plasma HIV RNA level is consistently negative, quantify the HIV proviral DNA load, and note changes in proviral DNA with combination antiretroviral therapies. The proviral DNA load is a measure of the reservoir cells which must be eliminated prior to stopping combination antiretroviral therapy.


1. Saget BM, Elbeik T, Guthries J, Drews B, and Scheibel S. Dramatic suppression of HIV-I plasma RNA using a combination of zidovudine, didanosine, zalcitabine, Epivir, and interferon-alpha in subjects with recent HIV-I infection. XI International Conference on AIDS, Vancouver, July 7-12 [abstract # We.B.533].

1592 -- New Experimental Antiretroviral

by John S. James
An experimental drug code-named 1592U89 (or 1592 for short) is a new kind of nucleoside analog which appears to have a much stronger anti-HIV effect than AZT, ddI, or other approved nucleoside analogs. It is now in phase I/II human testing, with one trial giving the drug to about 80 patients. Volunteers have had average viral load reductions of about 95 to 99 percent (approximately 1.5 to 2.2 logs), and average CD4 count increases of 79 to 127, at four weeks of treatment with this drug alone, and this improvement was sustained for the remaining eight weeks of the study. The drug has a short but acceptable half life in the blood (1 to 1.3 hours in early human tests; a shorter half life usually means more frequent doses are needed, but the results above were obtained with no more than three times daily dosing), and a fairly good ability to cross the blood-brain barrier.

The patients in this trial had CD4 counts of 200-500, and less than 12 weeks of prior use of AZT.

1592 is being developed by Glaxo Wellcome. There is growing interest in the possibility of compassionate-use access to this drug for patients who have failed other treatment options.


Saag M, Lancaster D, Sonnerborg A, and others.
Preliminary data on the safety and antiviral effect of 1592U89, alone and in combination with zidovudine (ZVD) in HIV-infected patients with CD4+ counts 200-500/mm3. XI International Conference on AIDS, Vancouver, July 7-12 [abstract # Th.B.294].

McDowell JA, Symonds WT, LaFon SW. Single-dose and steady- state pharmacokinetics of escalating regimens of 1592U89 with and without zidovudine. XI International Conference on AIDS, Vancouver, July 7-12 [abstract # Mo.B.1140].

Note to Readers

We postponed articles on the recently announced important discoveries involving the co-receptor CKR-5, on the August 2 final report of The Keystone National Policy Dialogue on Establishment of Studies to Optimize Medical Management of HIV Infection, and on Vancouver conference materials, to allow further checking and to make sure that our information is as current as possible.

Medical Marijuana: California Update

by John S. James
As we reported in our last issue, on August 4 the Cannabis Buyers' Club in San Francisco was raided by the office of California Attorney General Dan Lungren, who acted without informing San Francisco police and city officials. The club is still closed, depriving thousands of people with AIDS, cancer, and other major illnesses of safe access to medical marijuana. Some have collected their documentation and applied again at much smaller buyers' clubs in Oakland and Santa Cruz; many others have had to buy marijuana on the streets, at considerable risk for persons who are unfamiliar with the street dealer scene and also are seriously ill. Many of their stories have been told in the major news media.

We have seldom seen an issue which left people more angry and upset. There is near-universal revulsion toward the politically ambitious state attorney general and the other California officials who are widely seen to have acted for political purposes in depriving many people with major illnesses of a treatment vitally important to them.

There is widespread agreement that the important issues now are1 access to marijuana for those with urgent medical need, 2 return of the confidential medical records of almost 12,000 people, which were seized August 4, and3 passage of California Proposition 215 in the November election, to make it clear that doctors and patients who use marijuana for legitimate medical purposes are not criminals under California law. Since the raid, at least two major medical organizations -- the San Francisco Medical Society, and the California Academy of Family Physicians -- have publicly supported Proposition 215. No major medical organization has opposed it.

On August 9 the Cannabis Buyers' Club answered charges against it. For example, on the allegation that they sold to teenagers, CBC said that the teenager was given the marijuana by his mother, an undercover narcotics officer who bought it at the club. On the allegation that there were sales to non- medical users, the CBC admitted that some had slipped through with fraudulent documentation, and that the CBC needs to tighten its procedures.

On August 15 the San Francisco city government rejected a proposal to declare a state of medical emergency in order to allow the CBC to operate. AIDS prevention groups were concerned that this declaration might cause needle exchange in San Francisco to be shut down, since it now operates under a similar declaration of medical emergency, despite opposition from Lungren.

Persons with a documented medical need for medical marijuana may still be able to get it through other cannabis buyers' clubs; see our list of California organizations, below. Also, note the list of organizations working for passage of Proposition 215.


Opponents of Proposition 215 argue that medical marijuana is being used as a wedge issue to legalize drugs. (Incidentally, a similar argument is used against needle exchange.) This is hard to understand, since morphine and other drugs are widely used medically, without that causing any push toward their legalization for non-medical purposes. The public can easily separate the issues of urgent medical need vs. recreational use.

There is also widespread misunderstanding of the role of Marinol(R) (dronabinol), a legal prescription drug which contains THC, a major active ingredient of marijuana; opponents of medical marijuana say patients should use Marinol instead. But anyone who knows the people affected realizes that because individual patients are different, some can use marijuana but not Marinol (and others can use Marinol but not marijuana). The appropriate medical care is to have both available, so that individuals can use whichever works best for them. (Marinol is believed to be about three times as expensive as marijuana to use; we could not confirm this figure as marijuana prices and potencies vary greatly.)

Meanwhile, the Federal government continues to block medical research into medical use of marijuana, almost certainly for political reasons. And under President Bush, the Federal government closed its emergency medical access program which had been running well until then; President Clinton, who "did not inhale"and does not want the marijuana issue used against him again, has been unwilling to reconsider the Federal hostility toward medical access, despite overwhelming public support for it.

On August 15 Clinton's new drug czar, retired Army general Barry McCaffrey, attacked Proposition 215 in a press conference on Haight Street in San Francisco, saying "There is not a shred of scientific evidence that shows that smoked marijuana is useful or needed," according to the SAN FRANCISCO CHRONICLE, August 16. While that statement is easy to refute, the main issue is that information is indeed lacking because the U.S. has prohibited medical research on how to use marijuana as medicine.

While preparing this article we checked the literature on adverse effects of marijuana. Much of what we found is scientifically ludicrous. This literature is filled with reports of a handful of people (sometimes only one) who had smoked marijuana and were diagnosed with some illness -- with the implication that marijuana was a likely cause. Since millions of people receive medical care for serious illnesses, and many of them smoke marijuana, there must be hundreds of thousands in both categories by chance alone; finding a handful of examples proves nothing. What this literature does show is the desperate grasp for something, anything, that can be used as scientific cover for political efforts to keep the drug wars going.

The real fear may be that medical marijuana could indeed be a wedge issue -- not to legalize drugs, but to allow rational discussion of the overall costs and benefits of the current "war on drugs" approach to policy, and creative consideration of new options. The medical issue could open doors to re- thinking which otherwise are closed, since it is almost impossible to demonize sick people who use an illegal drug for urgent medical reasons, and much easier to demonize other users.

But any change threatens powerful interests, since the war on drugs has become an economic base for major industries, including law enforcement, unprecedented prison operation and construction, and a whole cluster of supporting economic activity -- as well as a funding stream for many government bodies through seized property, and a benefit to politicians and the press, who can use police stories to distract and entertain the public. In addition, the multi-billion dollar illegal drug industry absolutely depends on prohibition, as it could not exist otherwise; and this industry has influence even though it is illegal. All this could be threatened by a re-thinking of drug policy free of the overlay of demonization. The focus could then be on the costs we all pay in the misdirection of resources and the degradation of our quality of life.

What shapes certain kinds of institutional madness is empire building -- the normal tendency for institutions (both public and private, legal and illegal) to expand their role, influence, power, and prestige. What drives this process is the natural desire of individuals to get ahead, to become more important in their jobs. Growth is not wrong, but without effective public scrutiny, institutions can become self-perpetuating -- expanding without regard to any public purpose, and becoming parasitic, wasteful, and cruel.

All eligible Californians have a vital interest in registering and voting in this election -- whatever they might think of certain candidates on the ballot. Proposition 215 might open doors to new thinking beyond drug policy, on the larger issues of dysfunctional institutions and their tragic consequences for national and personal life.

Cannabis Buyers' Clubs in California:

Oakland CBC
P.O. Box 24590, Oakland, CA 94623
phone 510/832-5346, fax 510/986-0534

Santa Cruz CBC
201 Maple St., Santa Cruz

CBC Marin
contact Lynnette Shaw
415/253-4374 voicemail/pager

Los Angeles CBC
8159 Santa Monica Blvd., Suite 200
West Hollywood, CA 90046
phone 213/654-8910, fax 213/654-7833

Wo/Men's Alliance for Medical Marijuana (WAMM)
1803 Mission Street
Suite 553, Santa Cruz, CA 95060
phone/fax 408/423-5413
(Note: This group does not identify as a "buyers' club" per se;
WAMM does not charge for dispensing medical marijuana
but accepts donations.)

Note: San Francisco's Cannabis Buyers' Club can be reached through
Californians for Compassionate Use (see contact information below).
Due to an injunction against it, the CBC is not distributing medical marijuana
at this time, but is focusing instead on passage of Proposition 215.

Organizations Working for Proposition 215

Californians for Medical Rights (CMR)
1250 Sixth Street #202
Santa Monica, CA 90401
310/394-2952, fax 310/451-7494
CMR is the official sponsor of Proposition 215.
Other groups are also working for this Proposition, but they are separate.

Californians for Compassionate Use
1444 Market Street
San Francisco
415/621-3986, fax 415/621-0604

Southern Californians for Compassionate Use (SCCU)
8159 Santa Monica Blvd. Suite 200
West Hollywood, CA 90046
phone 213/874-4155, fax 213/874-4211
website .

Cannabis Action Network
2560 Bancroft Way #46
Berkeley, CA 94704
phone and fax 510/486-8083

Friends of Prop. 215
2560 Bancroft Way #195
Berkeley, CA 94704
phone 510/486-8090, fax 510/486-8083

Marin Alliance for Medical Marijuana
210 School St. Plaza
Fairfax, CA 94930, 415/893-1811

Wo/Men's Alliance for Medical Marijuana (WAMM)
1803 Mission Street, Suite 553
Santa Cruz, CA 95060
phone/fax 408/423-5413


(1) The above list only includes organizations actively working for passage of Proposition 215 -- not the much larger list of endorsers

(2) The major organization opposed to Proposition 215 is Citizens for a Drug Free California,
"a Project of Citizens for Economic Progress, Sheriff Brad Gates, Chairman,"
4901 Birch Street
Newport Beach, CA 92660

(3) Our lists above include organizations working on medical marijuana; many others focus on drug policy concerns. For example, see the excellent newsletter of California NORML (National Organization to Reform Marijuana Laws), available from :
NORML, 2215-R Market Street, #278
San Francisco, CA 94114

Calendar of AIDS 
Research andTreatment Meetings, 
Late 1996 and Beyond

There is no complete list of AIDS research/treatment conferences; here are some which have come to our attention. Let us know of any others which should be listed; we will publish updates occasionally.

This calendar includes: scientific or clinical conferences which are open to the public and are likely to release new information relevant to AIDS/HIV treatment; meetings on related topics, such as viral hepatitis, complementary AIDS/HIV treatments, or managed care; and some exceptional meetings for educating the public on AIDS treatment and research. We are compiling a separate list of vaccine meetings. This calendar focuses on September through December 1996, but includes some meetings after 1996 which came to our attention.

We have verified the following information in August 1996, unless otherwise stated; we have not verified all email addresses. Meeting times often change after announcements have been published, so check with the contact person or organization before making travel plans.

September 1996

Mechanisms of AIDS Pathogenesis
September 5-6
Rockville, Maryland.
Contact: Opendra Sharma
Division of AIDS, NIAID

Project Inform Town Meeting
Strategies for Survival and Update from the XI International Conference on AIDS.

September 5, 6:30 p.m. - 9:00 p.m.
Free Holders Chamber, Administrative Annex
567 Pavonia Ave., 3rd Floor
Jersey City, NJ.
Contact: Project Inform,
1965 Market Street, Suite 220
San Francisco, CA 94103
415/558-0684 fax
415/558-9051 or 800/822-7422 Treatment Hotline
website .

Note: Other meetings will be conducted in this fall in Little Rock, Washington D.C., Miami, and Ft. Lauderdale; dates, times, and locations will be announced.

Individuals may obtain a printed copy of the slides used during the presentation of these meetings by calling the Treatment Hotline numbers above and requesting "the latest overheads for the Project Inform Town Meeting and Vancouver report back."

Project Inform Town Meeting
Strategies for Survival and Update from the XI International Conference on AIDS
Minority Task Force on AIDS.

September 6, 2:00 p.m. - 5:00 p.m.
475 Riverside Drive at 120th Street
(Sockman Lounge--enter building at 61 Claremont Avenue)
Harlem, NY.
See September 5 announcement, above.

The 7th European Conference for Nurses in AIDS Care
September 11-14
Gothenburg, Sweden.
Contact: EANAC/Inger Petersen
+46 31 63 0500
fax +46 31 63 0510.
(Not confirmed at press time.)

(36th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy)

September 15-18
New Orleans, LA.
Press questions/registration:
Jim Sliwa, ASM (American Society for Microbiology),
fax 202/942-9367
other registration/program questions:
Debbie Atwood, ASM Meetings Department,
fax 202/942-9340.

(Relatively little new AIDS information is expected this year; AIDS TREATMENT NEWS is not going to ICAAC this time. We do suggest following AIDS reports from the meeting through the free conference calls organized by BETA, a treatment newsletter of the San Francisco AIDS Foundation, on September 16 and 17 -- see listings below. ICAAC focuses on new antibiotics, and is most likely to be strong on AIDS in odd-numbered years when the International Conference on AIDS does not occur. Note: We have been told that this year, photography will be allowed in the poster exhibits, although the printed program may say otherwise -- but no photography, and probably no tape recording either, will be allowed in oral sessions. Check with ASM if necessary.)

Conference call:
Updates from the 36th ICAAC
(Interscience Conference on Antimicrobial Agents and Chemotherapy)

September 16, also September 17.
800/707-BETA to register.

(Note: These free conference calls are presented by BETA, the quarterly AIDS treatment magazine published by the San Francisco AIDS Foundation; during each call you can listen to and ask questions of a panel of experts. To join either or both calls, you must register in advance at the contact number above, which can be done 24 hours a day; one may want to register for both calls, as ICAAC will be ongoing, so different information will be presented. Both the September 16 and September 17 calls will be 4:00 p.m. Pacific Time, 5:00 p.m. Mountain, 6:00 p.m. Central, and 7:00 p.m. Eastern. If you miss the calls, there might be facilities for listening to them later; call the registration number above to find out. You can still hear recordings of similar calls which took place during the Vancouver conference. This program supported by an educational grant from Hoffmann-La Roche.)

First Annual Disease Management Conference
September 16-19
Washington DC.
Contact: Amy Corcoran
Disease Management Congress
fax 617/270-6107
email .

(Comment: "Disease management" is today's buzzword for an approach to fixing some of the problems of managed care. We know little about this particular conference, except that it has been extensively publicized. It is not specifically focused on AIDS; we included it for readers who may want to look into the disease-management movement.)

Conference call:
Updates from the 36th ICAAC
(Interscience Conference on Antimicrobial Agents and Chemotherapy)
September 17.
Contact: 800/707-BETA to register.
(See information in September 16 listing, above.)

First National Harm Reduction Conference
September 18-21
Oakland, California.
Contact: The Harm Reduction Coalition
3223 Lakeshore Avenue
Oakland, CA 94610
phone 510/444-6969
fax 510/444-6977
website .

(Note: The concept of harm reduction focuses on strategies, such as needle exchange programs, to diminish the adverse consequences of drug use and other life-threatening activities.)

Infectious Diseases Society of America (IDSA)
34th Annual Meeting
September 18-20
New Orleans, LA.
800/424-5249 or 847/940-2155
fax 800/521-6017 or 847/940-2386.

These contact numbers are for travel, etc. arrangements; IDSA itself can be reached at 703/299-0200. (In this meeting, several hundred doctors gather in an auditorium to listen all day to lectures on infectious diseases, including AIDS, from leading experts. Few AIDS activists attend. This year the dates are coordinated with ICAAC, so it is possible to go to both meetings with the same trip to New Orleans; but next year for the first time the organizations will meet separately, with IDSA holding its 1997 meeting in San Francisco.)

Managing Risk and Integrating Care for HIV/AIDS in a Managed Care Environment
September 18-20
San Francisco.
Managed Care Advisory Council
A division of the International Quality & Productivity Center
Lisa Steinhart
800/890-6215 ext. 438
fax 201/256-0205
website .

Comprehensive Nursing Management of HIV Disease
September 19-21
Miami Beach.
Sponsored by Florida AIDS Education and Training Centers Network
and Association of Nurses in AIDS Care, Metro Miami.
Contact: Sherri Armstrong
303/672-2100, ext. 3549.

AIDS Research Advisory Committee
September 27
Bethesda, Maryland.
Contact: Rona Siskind
Division of AIDS

AIDS Medicine: An Intensive Course
September 30 - October 1
Cambridge, MA.
Sponsored by Department of Medicine, Massachusetts General Hospital,
and Department of Medicine, Brigham and Women's Hospital.
Contact: Harvard MED-CME
P.O. Box 825
Boston, MA 02117-0825
website .

V International Symposium on Viral Hepatitis
September 30 - October 1
Contact: Technical Secretariat
fax +34-3-414-47-11;
or contact 34-1-358-11-91
fax 34-1-358-10-05.
(Not confirmed at press time.)

October 1996

[Note: Dozens of AIDS events will take place in Washington D.C. in early to mid October, at around the dates of the NAMES Project Quilt display, October 11-13 at The National Mall (contact: The NAMES Project AIDS Memorial Quilt, 202/296-2637, fax 202/296-4121, email, website for more information or to volunteer).

Since many thousands of people will be visiting the Quilt and related gatherings (just assisting the Quilt display will require over 12,000 volunteers), hotel rooms in Washington are already scarce.

2nd International Conference on Health and Human Rights
October 3-5
Cambridge, Massachusetts.
Contact: Francois-Xavier Bagnoud Center for Health and Human Rights
fax 617/496-4380.

National AIDS Treatment Advocates Forum
October 6-9
Contact: David Barre
National Minority AIDS Council
202/483-6622 ext. 327
fax 202/483-1135
website .

(Note: Dates are coordinated with the Sixth Annual National Skills Building Conference, below.)

Managing Risk and Integrating Care for HIV/AIDS in a Managed Care Environment
October 9-11
See September 18-20 listing, above.

New Insights in HIV Infection and Disease
Hilton Head, SC
October 9-14.
Cambridge Symposia
fax 617/630-1395
website .

Sixth Annual National Skills Building Conference
October 10-13
Washington D.C.
Contact: Registration
fax 202/483-1127.

This conference is sponsored by three organizations, the AIDS National Interfaith Network, 202/546- 0807; National Association of People with AIDS, 202/898-0414; and National Minority AIDS Council, 202/483-6622. It has reserved a block of rooms at the conference hotel, The Washington Hilton and Towers; reservations must be made by September 20 to obtain the conference rate. However, at press time, the nights of October 11 & 12 have been sold out at the Hilton and Towers; rooms are still available at the overflow hotels: Capitol Hilton, 202/393-1000, and the Radisson Barcelo Hotel Washington, 202/293-3100. Identify yourself as a conference participant to get the conference rate.

AIDS, Medicine, & Miracles
October 10
Washington D.C.
Contact: Charles Robbins
AIDS, Medicine, & Miracles
P.O. Box 20650
Boulder, CO
80308-3650, 800/875-8770, 303/447-8777
fax 303/447-3902

This one-day meeting, "What Holds Promise," is being held in conjunction with the National Skills Building Conference. Scheduled speakers include Charles Steinberg, M.D., Richard Elion, M.D., and Lark Lands, Ph.D.

48th Annual Meeting of the National Hemophilia Foundation
October 17-20
San Diego.
National Hemophilia Foundation
1-888/INFO-NHF ext. 3032
212/219-8180 ext. 3032
fax 212/966-9247.

Community Programs for Clinical Research on AIDS (CPCRA)
October 27-28
Crystal City, Virginia (near Washington).
Contact: Elaine Allison
CPCRA Operations Office
fax 301/230-7190
email .

November 1996

Quality of Care 11th Annual Symposium
November 2-3
Arlington, Virginia.
Contact: The Center for Clinical Quality Evaluation
fax 202/833-2047
website .

3rd International Congress on Drug Therapy in HIV Infection
November 3-7
Birmingham, United Kingdom.
Contact: Gardiner-Caldwell Communications Ltd.
fax +44-1625-610260.

Protease Inhibitors: New Therapeutics and Approaches
November 6-7
Contact: Cambridge Healthtech Institute
fax 617/630-1325
website .

(This meeting is not AIDS-specific, but includes HIV protease inhibitors among drugs for other viral infections, and for non-infectious diseases.)

AIDS, Medicine, & Miracles
November 7-10
Contact: Charles Robbins
AIDS, Medicine, & Miracles
P.O. Box 20650
Boulder, CO 80308-3650
800/875-8770, 303/447-8777, 303/447-3902
website .

This holistic retreat includes three one-day institutes -- one in Spanish, one for women with HIV, and one for caregivers and service organizations.

Annual Meeting of the American Public Health Association
November 17-21
New York City.
Contact: APHA
fax 202/789-5661
website .

The theme for this year is Empowering the Disadvantaged: Social Justice in Public Health.

HIV Surrogate Markers: Virological and Immunological Indicators
November 18-19
McLean, Virginia.
Cambridge Healthtech Institute
fax 617/630-1325
website .

Novel HIV Therapeutic Strategies
November 20-21
McLean, Virginia.
Cambridge Healthtech Institute
fax 617/630-1325
website .

December 1996

Clinical Care of the AIDS Patient
December 5-7
San Francisco.
Contact: University of California San Francisco
Department of Medicine
fax 415/476-3542
website .

AIDS Clinical Trials Group (ACTG)
December 7-11?
Contact: Ms. Bernstein


4th Conference on Retroviruses and Opportunistic Infections
dates to be announced
Contact: IDSA
fax 703/299-0204.

Until There Is a Cure
January 24-25
Bradenton, Florida.
Contact: Ray Efird
AIDS Manasota

(Not a research meeting, but a well-regarded conference on complementary and mainstream treatment options.)

AIDS Research Advisory Committee
January 24
Bethesda, Maryland.
Contact: Rona Siskind
Division of AIDS

Community Programs for Clinical Research on AIDS (CPCRA)
February 6-7
Washington, D.C.
Contact: Elaine Allison
Operations Office
fax 301/230-7190
email .

9th National AIDS Update
San Francisco
February 19-25.
Contact: Krebs Convention Services
fax 415/255-2244.

AIDS Pathogenesis
April 8-13
Keystone, Colorado.
Contact: Keystone Symposia
800/253-0685 or 970/262-1230
fax 970/262-1525
website .

Community Programs for Clinical Research on AIDS (CPCRA)
May 11-12
Reston, Virginia. Contact: Elaine Allison
CPCRA Operations Office
fax 301/230-7190
email .

11th Annual AIDS Update for Primary Care
June 6, 1997
Oakland, California.
Contact: Caroline Carey
Alta Bates Medical Center
fax 510/204-1221.

Bio'97 International Biotechnology Meeting & Exhibition
June 8-12
Contact: 202/857-0244
fax 202/331-8132
website .

(Biotechnology business focus; sponsored by BIO, the Biotechnology Industry Organization, "the world's largest trade organization to serve and represent the biotechnology industry." Program and registration material not available until January 1997.)

Fourth International Symposium on Clinical Immunology
June 19-22.
Contact: Conference Secretariat
4th International Symposium on Clinical Immunology
Amsterdam RAI-OBA
P.O. Box 77777
1070 MS Amsterdam
The Netherlands.
[Note: We could not verify this information by press time.]

AIDS Clinical Trials Group (ACTG)
July 18-23, 1997
Contact: NIAID

Community Programs for Clinical Research on AIDS (CPCRA)
September 4-5, 1997
Washington, D.C.
Contact: Elaine Allison
CPCRA Operations Office
fax 301/230-7190
email .

AIDS Clinical Trials Group (ACTG)
December 5-10, 1997
Arlington, Virginia (near Washington).
Contact: NIAID


12th World AIDS Conference
June 28 - July 3, 1998
Scholarship deadline February 1, 1988.
Contact: Congress Secretariat
12th World AIDS Conference
c/o Congrex (Sweden) AB
P.O. Box 5619
S-114 86 Stockholm, Sweden.
Phone +46 8 612 69 00
fax +46 8 612 62 92
website .

The international AIDS conference which recently occurred in Vancouver now occurs once every two years. For the 1998 meeting in Geneva, organizers plan "to make unprecedented use of computers during the conference and, in particular, to send the program and abstracts both on paper and on diskettes or CD to the participants before the Conference." This means that for the first time at the world AIDS conference, attenders will be able to prepare in advance and use the valuable time at the meeting to greater benefit. We also appreciate the improved and simplified name (12th World AIDS Conference, instead of the names such as XI International Conference on AIDS for the Vancouver meeting), and the simplified computer addresses.

The Geneva conference will include a major focus on treatment access for the 90% of people with HIV who live in the developing world, as the Vancouver conference did. The conference plans to spend at least 15% of its budget for scholarships to facilitate access for participants from developing countries.

Hopefully the Geneva meeting can equal Vancouver's outstanding cooperation with community organizations worldwide.

4th International Congress on Drug Therapy in HIV Infection
November 8-12, 1998
Glasgow, Scotland.
Contact: Gardiner-Caldwell Communications Ltd.
fax +44-1625-610260.

This article was provided by AIDS Treatment News. It is a part of the publication AIDS Treatment News. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.